Courage Capital Management LLC Galectin Therapeutics Inc Transaction History

Courage Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$3.68 - $6.93 $81,423 - $153,333	-22,126 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$3.16 - $9.16 $24,881 - $72,125	-7,874 Reduced 26.25%	22,126 $141,000
Q1 2018 May 14, 2018	SELL	$3.78 - $5.97 $75,600 - $119,400	-20,000 Reduced 40.0%	30,000 $142,000
Q4 2017 Feb 14, 2018	SELL	$1.54 - $3.34 $123,200 - $267,200	-80,000 Reduced 61.54%	50,000 $167,000
Q2 2017 Aug 14, 2017	BUY	N/A	130,000	130,000 $320,000

9.69M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Courage Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Courage Capital Management LLC with notifications on news.